356 related articles for article (PubMed ID: 16505286)
1. Immunohistological characterisation of tumour infiltrating lymphocytes in melanocytic skin lesions.
Hussein MR; Elsers DA; Fadel SA; Omar AE
J Clin Pathol; 2006 Mar; 59(3):316-24. PubMed ID: 16505286
[TBL] [Abstract][Full Text] [Related]
2. TIA-1 positive tumor-infiltrating lymphocytes in nevi and melanomas.
Lyle S; Salhany KE; Elder DE
Mod Pathol; 2000 Jan; 13(1):52-5. PubMed ID: 10658910
[TBL] [Abstract][Full Text] [Related]
3. Antigenic profile of tumor progression stages in human melanocytic nevi and melanomas.
Elder DE; Rodeck U; Thurin J; Cardillo F; Clark WH; Stewart R; Herlyn M
Cancer Res; 1989 Sep; 49(18):5091-6. PubMed ID: 2548711
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of tumour-infiltrating CD4+CD25+FOXP3+ regulatory T cells in human cutaneous benign and atypical naevi, melanomas and melanoma metastases.
Mourmouras V; Fimiani M; Rubegni P; Epistolato MC; Malagnino V; Cardone C; Cosci E; Nisi MC; Miracco C
Br J Dermatol; 2007 Sep; 157(3):531-9. PubMed ID: 17596146
[TBL] [Abstract][Full Text] [Related]
5. Infiltrating lymphocytes in benign and malignant naevomelanocytic lesions.
Flageul B; Bachelez H; Boumsell L; Degos L; Bensussan A
Nouv Rev Fr Hematol (1978); 1990; 32(1):9-11. PubMed ID: 2349086
[TBL] [Abstract][Full Text] [Related]
6. Inducible nitric oxide synthase expression in benign and malignant cutaneous melanocytic lesions.
Massi D; Franchi A; Sardi I; Magnelli L; Paglierani M; Borgognoni L; Maria Reali U; Santucci M
J Pathol; 2001 Jun; 194(2):194-200. PubMed ID: 11400148
[TBL] [Abstract][Full Text] [Related]
7. Utility of tumour-infiltrating CD25+FOXP3+ regulatory T cell evaluation in predicting local recurrence in vertical growth phase cutaneous melanoma.
Miracco C; Mourmouras V; Biagioli M; Rubegni P; Mannucci S; Monciatti I; Cosci E; Tosi P; Luzi P
Oncol Rep; 2007 Nov; 18(5):1115-22. PubMed ID: 17914561
[TBL] [Abstract][Full Text] [Related]
8. The initial steps of tumor progression in melanocytic lineage: a histochemical approach.
Wollina U; Kilian U; Henkel U; Schaarschmidt H; Knopf B
Anticancer Res; 1991; 11(4):1405-14. PubMed ID: 1746897
[TBL] [Abstract][Full Text] [Related]
9. Study of the immunophenotype of the inflammatory cells in melanomas with regression and halo nevi.
Botella-Estrada R; Kutzner H
Am J Dermatopathol; 2015 May; 37(5):376-80. PubMed ID: 25222195
[TBL] [Abstract][Full Text] [Related]
10. Flow cytometry assessment of residual melanoma cells in tumor-infiltrating lymphocyte cultures.
Richards JO; Treisman J; Garlie N; Hanson JP; Oaks MK
Cytometry A; 2012 May; 81(5):374-81. PubMed ID: 22467596
[TBL] [Abstract][Full Text] [Related]
11. Melanocytic dysplastic naevi occupy the middle ground between benign melanocytic naevi and cutaneous malignant melanomas: emerging clues.
Hussein MR
J Clin Pathol; 2005 May; 58(5):453-6. PubMed ID: 15858113
[TBL] [Abstract][Full Text] [Related]
12. Gene expression profiling of primary cutaneous melanoma.
Winnepenninckx V; Van den Oord JJ
Verh K Acad Geneeskd Belg; 2007; 69(1):23-45. PubMed ID: 17427873
[TBL] [Abstract][Full Text] [Related]
13. Immunohistological analysis of immune cells in blistering skin lesions.
Hussein MR; Ali FM; Omar AE
J Clin Pathol; 2007 Jan; 60(1):62-71. PubMed ID: 17213348
[TBL] [Abstract][Full Text] [Related]
14. CD20+ tumor-infiltrating lymphocytes have an atypical CD27- memory phenotype and together with CD8+ T cells promote favorable prognosis in ovarian cancer.
Nielsen JS; Sahota RA; Milne K; Kost SE; Nesslinger NJ; Watson PH; Nelson BH
Clin Cancer Res; 2012 Jun; 18(12):3281-92. PubMed ID: 22553348
[TBL] [Abstract][Full Text] [Related]
15. Micro-anatomy related antigen expression in melanocytic lesions.
Meije CB; Mooi WJ; Le Poole IC; Van Muijen GN; Das PK
J Pathol; 2000 Apr; 190(5):572-8. PubMed ID: 10727983
[TBL] [Abstract][Full Text] [Related]
16. Defective lymphokine production by most CD8+ and CD4+ tumor-specific T cell clones derived from human melanoma-infiltrating lymphocytes in response to autologous tumor cells in vitro.
Guilloux Y; Viret C; Gervois N; Le Dréan E; Pandolfino MC; Diez E; Jotereau F
Eur J Immunol; 1994 Sep; 24(9):1966-73. PubMed ID: 7522155
[TBL] [Abstract][Full Text] [Related]
17. Adhesion molecule profile and malignancy of melanocytic lesions.
Moretti S; Martini L; Berti E; Pinzi C; Giannotti B
Melanoma Res; 1993 Aug; 3(4):235-9. PubMed ID: 8219755
[TBL] [Abstract][Full Text] [Related]
18. Characteristics of cultured human melanocytes isolated from different stages of tumor progression.
Herlyn M; Thurin J; Balaban G; Bennicelli JL; Herlyn D; Elder DE; Bondi E; Guerry D; Nowell P; Clark WH
Cancer Res; 1985 Nov; 45(11 Pt 2):5670-6. PubMed ID: 4053039
[TBL] [Abstract][Full Text] [Related]
19. Local immune response predicts survival in patients with thick (t4) melanomas.
Cintolo JA; Gimotty P; Blair A; Guerry D; Elder DE; Hammond R; Elenitsas R; Xu X; Fraker D; Schuchter LM; Czerniecki BJ; Karakousis G
Ann Surg Oncol; 2013 Oct; 20(11):3610-7. PubMed ID: 23838911
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma.
Tomsová M; Melichar B; Sedláková I; Steiner I
Gynecol Oncol; 2008 Feb; 108(2):415-20. PubMed ID: 18037158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
